Literature DB >> 2492910

Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1.

P Roux-Lombard1, C Modoux, A Cruchaud, J M Dayer.   

Abstract

The production of tumor necrosis factor alpha (TNF alpha) and interleukin 1 (IL-1) was measured in supernatants of cultured peripheral blood monocytes that were obtained from patients with human immunodeficiency virus type 1 (HIV 1) infection and that were purified by counterflow centrifugal elutriation (86-92% purity). TNF alpha levels were significantly higher in monocytes isolated from symptomatic HIV 1-infected patients as compared to normal controls. Although IL-1 levels were also elevated in this group of symptomatic patients they did not reach statistical significance. The production of the two monokines was intermediate in asymptomatic HIV 1-infected individuals. The increase of TNF alpha was observed in the absence of in vitro stimulation as well as in the presence of interferon-gamma plus lipopolysaccharide. TNF alpha and IL-1 were measured by radioimmunoassay and by bioassay, the results of the two methods being highly correlated for both cytokines. The levels of TNF alpha and IL-1 were also positively correlated. These data suggest that IL-1 and TNF alpha may be involved in the pathogenesis of HIV 1 infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492910     DOI: 10.1016/0090-1229(89)90144-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  42 in total

Review 1.  Impaired regulation of HLA-DR expression in human immunodeficiency virus-infected monocytes.

Authors:  Ling Shao; Kirk Sperber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  Spontaneous release of interferon as a predictor of clinical evolution in HIV-positive subjects.

Authors:  A Biglino; A Surbone; F Lipani; N Cappello; B Forno; A M Pollono; M Busso; A Pugliese
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

3.  Macronutrient intake and malabsorption in HIV infection: a comparison with other malabsorptive states.

Authors:  F Carbonnel; L Beaugerie; A Abou Rached; H D'Almagne; W Rozenbaum; Y Le Quintrec; J P Gendre; J Cosnes
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

4.  Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infection.

Authors:  M Weiss; M Martignoni; T Petropoulou; B Sölder; B H Belohradsky
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

5.  Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes.

Authors:  D Emilie; M Peuchmaur; M C Maillot; M C Crevon; N Brousse; J F Delfraissy; J Dormont; P Galanaud
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

Review 6.  Evaluation of TNF as antiviral, antibacterial and antiparasitic agent.

Authors:  G A Rook; J Taverne; J H Playfair
Journal:  Biotherapy       Date:  1991

7.  High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients.

Authors:  D Hober; S Benyoucef; A S Delannoy; D de Groote; F Ajana; Y Mouton; P Wattré
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

8.  Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes.

Authors:  A Kalinkovich; G Livshits; H Engelmann; N Harpaz; R Burstein; M Kaminsky; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells.

Authors:  J M Molina; D T Scadden; C Amirault; A Woon; E Vannier; C A Dinarello; J E Groopman
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

10.  Relationship between tumor necrosis factor alpha and feline immunodeficiency virus expressions.

Authors:  L A Kraus; W G Bradley; R W Engelman; K M Brown; R A Good; N K Day
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.